The transcription factor GATA1 and the histone methyltransferase SET7 interact to promote VEGF-mediated angiogenesis and tumor growth and predict clinical outcome of breast cancer

被引:46
作者
Zhang, Yanan [1 ,2 ]
Liu, Jie [1 ]
Lin, Jing [3 ]
Zhou, Lei [4 ]
Song, Yuhua [5 ]
Wei, Bo [6 ]
Luo, Xiaoli [1 ]
Chen, Zhida [1 ,6 ]
Chen, Yingjie [1 ,5 ]
Xiong, Jiaxiu [1 ,6 ]
Xu, Xiaojie [1 ]
Ding, Lihua [1 ]
Ye, Qinong [1 ,2 ]
机构
[1] Beijing Inst Biotechnol, Collaborat Innovat Ctr Canc Med, Dept Med Mol Biol, Beijing, Peoples R China
[2] Dalian Med Univ, Ctr Canc, Inst Canc Stem Cell, Liaoning, Peoples R China
[3] Chinese Peoples Liberat Army Gen Hosp, Affiliated Hosp 1, Beijing 100853, Peoples R China
[4] Capital Med Univ, Beijing Shijitan Hosp, Beijing, Peoples R China
[5] Qing Dao Univ, Affiliated Hosp, Qingdao, Peoples R China
[6] Chinese Peoples Liberat Army Gen Hosp, Dept Gen Surg, Beijing 100853, Peoples R China
基金
北京市自然科学基金;
关键词
VEGF; angiogenesis; tumor growth; GATA1; SET7; LYSINE METHYLTRANSFERASE; ESTROGEN-RECEPTOR; PROSTATE-CANCER; GENE-EXPRESSION; A EXPRESSION; IN-VIVO; CELLS; METHYLATION; PROLIFERATION; DIFFERENTIATION;
D O I
10.18632/oncotarget.7126
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Angiogenesis is essential for tumor growth. Vascular endothelial growth factor (VEGF) is the most important regulator of tumor angiogenesis. However, how transcription factors interact with histone-modifying enzymes to regulate VEGF transcription and tumor angiogenesis remains unclear. Here, we show that transcription factor GATA1 associates with the histone methyltransferase SET7 to promote VEGF transcription and breast tumor angiogenesis. Using chromatin immunoprecipitation assay, we found that GATA1 was required for recruitment of SET7, RNA polymerase II and transcription factor II B to VEGF core promoter. GATA1 enhanced breast cancer cell (MCF7, ZR75-1 and MDA-MB-231)-secreted VEGF via SET7, which promoted vascular endothelial cell (HUVEC) proliferation, migration and tube formation. SET7 was required for GATA1-induced breast tumor angiogenesis and growth in nude mice. Immunohistochemical staining showed that expression of GATA1 and SET7 was upregulated and positively correlated with VEGF expression and microvessel number in 80 breast cancer patients. GATA1 and SET7 are independent poor prognostic factors in breast cancer. Our data provide novel insights into VEGF transcriptional regulation and suggest GATA1/SET7 as cancer therapeutic targets.
引用
收藏
页码:9859 / 9875
页数:17
相关论文
共 50 条
  • [1] Histone methylase MLL1 has critical roles in tumor growth and angiogenesis and its knockdown suppresses tumor growth in vivo
    Ansari, K. I.
    Kasiri, S.
    Mandal, S. S.
    [J]. ONCOGENE, 2013, 32 (28) : 3359 - 3370
  • [2] GATA-1 and c-myb crosstalk during red blood cell differentiation through GATA-1 binding sites in the c-myb promoter
    Bartunek, P
    Králová, J
    Blendinger, G
    Dvorák, M
    Zenke, M
    [J]. ONCOGENE, 2003, 22 (13) : 1927 - 1935
  • [3] The transcription factor GATA-1 is overexpressed in breast carcinomas and contributes to survivin upregulation via a promoter polymorphism
    Boidot, R.
    Vegran, F.
    Jacob, D.
    Chevrier, S.
    Cadouot, M.
    Feron, O.
    Solary, E.
    Lizard-Nacol, S.
    [J]. ONCOGENE, 2010, 29 (17) : 2577 - 2584
  • [4] VEGF as a key mediator of angiogenesis in cancer
    Carmeliet, P
    [J]. ONCOLOGY, 2005, 69 : 4 - 10
  • [5] Covalent histone modifications - miswritten, misinterpreted and mis-erased in human cancers
    Chi, Ping
    Allis, C. David
    Wang, Gang Greg
    [J]. NATURE REVIEWS CANCER, 2010, 10 (07) : 457 - 469
  • [6] Regulation of VEGF/VPF expression in tumor cells: Consequences for tumor growth and metastasis
    Claffey, KP
    Robinson, GS
    [J]. CANCER AND METASTASIS REVIEWS, 1996, 15 (02) : 165 - 176
  • [7] VEGF-targeted therapy: mechanisms of anti-tumour activity
    Ellis, Lee M.
    Hicklin, Daniel J.
    [J]. NATURE REVIEWS CANCER, 2008, 8 (08) : 579 - 591
  • [8] The biology of VEGF and its receptors
    Ferrara, N
    Gerber, HP
    LeCouter, J
    [J]. NATURE MEDICINE, 2003, 9 (06) : 669 - 676
  • [9] Fischle W, 2012, EPIGENOMICS-UK, V4, P641, DOI [10.2217/EPI.12.56, 10.2217/epi.12.56]
  • [10] Forsythe JA, 1996, MOL CELL BIOL, V16, P4604